Universidad de Cordoba   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Cordoba Spain (1972)

Organization Overview

First Clinical Trial
2005
NCT00324558
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Complejo Hospitalario Universitario Reina Sofía | Departamento de Enfermería, Farmacología y Fisioterapia, Universidad de Córdoba, Córdoba, España | Hospital General Universitario Reina Sofía | Hospital General Universitario Reina Sofía de Murcia | Hospital General Universitario Reina Sofía (SPAIN) | Hospital Reina Sofia, Cordoba | Hospital Reina Sofia - Córdoba | Hospital Reina Sofia (Córdoba) | Hospital Reina Sofia, Cordoba, Spain | Hospital Reina Sofia. Córdoba. Spain | Hospital Reina Sofia, Murcia | Hospital Universitario Reina Sofía | Hospital Universitario Reina Sofia | Hospital Universitario Reina Sofia. Cordoba | Hospital Universitario Reina Sofia (Cordoba) Spain | Hospital Universitario Reina Sofía, Córdoba, Spain | H. Reina Sofia | IMIBIC/ Reina Sofia University Hospital / University of Cordoba | Instituto Maimonides de Investigacion Biomedica de Cordoba | Instituto Maimonides de Investigación Biomedica de Cordoba | Instituto Maimonides de Investigación Biomédica de Córdoba | Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) | Instituto Maimonides de Investigacion Biomedica de Cordoba, Spain | Isaac Tunez-Fiñana | Maimónides Biomedical Research Institute of Córdoba | Reina Sofia Hospital | Reina Sofia University Hospital | Universidad de Cordoba | Universidad de Córdoba | Universidad de Córdoba - España | Universidad Nacional de Córdoba | University Hospital Reina Sofía, Córdoba.

Active Ingredients

Drugs in Phase 4 Trials (6)

albumin (Human) (Plasbumin) (1 trial)

ciclopirox (loprox) (1 trial)

furosemide (lasix) (1 trial)

infliximab (remicade) (1 trial)

solifenacin (vesicare) (1 trial)

torsemide (demadex) (1 trial)

Drugs in Phase 3 Trials (10)

cabazitaxel (jevtana kit) (1 trial)

cyclosporine (sandimmune) (1 trial)

etoricoxib (Gencox) (1 trial)

ganciclovir (cytovene) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

mitomycin (mutamycin) (1 trial)

mycophenolate (CellCept) (1 trial)

prednisone (meticorten) (1 trial)

ribavirin (virazole) (1 trial)

valganciclovir (Valcyte) (1 trial)

Drugs in Phase 2 Trials (25)

allopurinol (zyloprim) (1 trial)

autologous bone marrow derived mesenchymal cells (1 trial)

azithromycin (zithromax) (1 trial)

bevacizumab (avastin) (1 trial)

bone autograft (1 trial)

calcifediol (1 trial)

cetuximab (erbitux) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

dexamethasone (1 trial)

enoxaparin (lovenox) (1 trial)

fluorouracil (efudex) (1 trial)

human fecal microbiota (Reybota) (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

letermovir (prevymis) (1 trial)

leucovorin (1 trial)

modified recombinant fish parvalbumin (1 trial)

olaparib (lynparza) (1 trial)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (1 trial)

pomalidomide (pomalyst) (1 trial)

pomegranate (2 trials)

sarilumab (kevzara) (1 trial)

trastuzumab (herceptin) (1 trial)

tucatinib (Tukysa) (1 trial)

vinorelbine (navelbine) (1 trial)

Drugs in Phase 1 Trials (2)

acetylcysteine (mucomyst) (1 trial)

anacaulase (NexoBrid) (1 trial)

Drugs in Other Trials (21)

beetroot juice (1 trial)

bifidobacterium breve (1 trial)

bifidobacterium lactis (1 trial)

bifidobacterium longum (1 trial)

bovine lactoferrin (1 trial)

docosahexaenoic acid (1 trial)

Lactobacillus acidophilus (1 trial)

lactobacillus bulgaricus (1 trial)

lactobacillus fermentum (1 trial)

lactobacillus rhamnosus (1 trial)

loperamide (imodium) (1 trial)

medium chain triglyceride (1 trial)

olive (1 trial)

omega-3 fatty acids (Omacor) (1 trial)

polyphenols (1 trial)

sorbitol (1 trial)

soybean oil (Intralipid) (1 trial)

sterculia gum (1 trial)

Streptococcus thermophilus (1 trial)

sunflower oil (1 trial)

ubiquinone (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Arthritis (Phase 4)

Bacterial Infections (Phase 4)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Small Cell (Phase 2)

Cholangitis (Phase 4)

Colorectal Neoplasms (Phase 3)

Communicable Diseases (Phase 3)

Coronavirus Infections (Phase 2)

Cytomegalovirus Infections (Phase 3)

Dermatomycoses (Phase 4)

Fever (Phase 2)

Fibrosis (Phase 4)

Food Hypersensitivity (Phase 2)

Heart Failure (Phase 4)

Hepatitis (Phase 3)

Hepatitis C (Phase 3)

HIV Infections (Phase 3)

Hyperkinesis (Phase 4)

Hypersensitivity (Phase 2)

Infections (Phase 4)

Liver Cirrhosis (Phase 3)

Liver Diseases (Phase 4)

Lupus Nephritis (Phase 3)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Nephritis (Phase 3)

Ovarian Neoplasms (Phase 2)

Peritoneal Neoplasms (Phase 2)

Pneumonia (Phase 4)

Prostatic Neoplasms (Phase 3)

Recurrence (Phase 3)

Severe Acute Respiratory Syndrome (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Spondylitis (Phase 4)

Spondylitis, Ankylosing (Phase 4)

Syndrome (Phase 2)

Urinary Bladder, Overactive (Phase 4)

Urinary Incontinence (Phase 4)

Urinary Tract Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 42
  • # of Trial APIs: 64